Temoporfin

Temoporfin
Systematic (IUPAC) name
3,3',3'',3'''-(2,3-dihydroporphyrin-5,10,15,20-tetrayl)tetraphenol
Clinical data
AHFS/Drugs.com International Drug Names
Licence data EMA:Link
Pregnancy cat.  ?
Legal status ℞ Prescription only
Identifiers
CAS number 122341-38-2
ATC code L01XD05
PubChem CID 60751
UNII FU21S769PF Y
KEGG D06066 Y
Chemical data
Formula C44H32N4O4 
Mol. mass 680.74 g/mol
SMILES eMolecules & PubChem
 Y(what is this?)  (verify)

Temoporfin (INN) is a photosensitizer (based on porphyrin) used in photodynamic therapy for the treatment of squamous cell carcinoma of the head and neck[1] .[2] It is marketed in the European Union under the brand name Foscan. The US FDA deemed Foscan non-approvable in 2000. The EU approved its use in June 2001.[3]

Good results were obtained in 21 of 35 patients treated in Germany.[4]

It is photoactivated at 652 nm[5] i.e. by red light.

Patients can remain photosensitive for several weeks after treatment.[2]

Further reading

References

  1. ^ Lorenz KJ, Maier H (April 2008). "[Squamous cell carcinoma of the head and neck. Photodynamic therapy with Foscan]" (in German). HNO 56 (4): 402–9. doi:10.1007/s00106-007-1573-1. PMID 17516041. 
  2. ^ a b O'Connor, Aisling E, Gallagher, William M, Byrne, Annette T (2009). "Porphyrin and Nonporphyrin Photosensitizers in Oncology: Preclinical and Clinical Advances in Photodynamic Therapy. Photochemistry and Photobiology, Sep/Oct 2009". Photochemistry and Photobiology. http://findarticles.com/p/articles/mi_qa3931/is_200909/ai_n42040200/pg_7/. 
  3. ^ http://www.highbeam.com/doc/1P2-18794532.html Foscan approval saves Scotia's skin.
  4. ^ http://www.springerlink.com/content/g74w224824v8l013/
  5. ^ "Porphyrin and Nonporphyrin Photosensitizers in Oncology: Preclinical and Clinical Advances in Photodynamic Therapy". Photochemistry and Photobiology. 2009. http://findarticles.com/p/articles/mi_qa3931/is_200909/ai_n42040200/pg_7/.